Last reviewed · How we verify
Brimonidine 0.33%
Brimonidine 0.33% is a Alpha-2 adrenergic agonist Small molecule drug developed by Derm Research, PLLC. It is currently FDA-approved for Persistent facial erythema associated with rosacea. Also known as: Miravaso, Onreltea.
Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces erythema (redness) in the skin.
Brimonidine 0.33% is a small molecule used to treat conditions such as rosacea, flushing, and acne rosacea. It is administered as a topical gel, often in comparison to a placebo vehicle gel, in clinical trials.
At a glance
| Generic name | Brimonidine 0.33% |
|---|---|
| Also known as | Miravaso, Onreltea |
| Sponsor | Derm Research, PLLC |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine selectively binds to alpha-2 adrenergic receptors on vascular smooth muscle cells, causing vasoconstriction that reduces blood flow to the skin surface. This mechanism decreases the appearance of facial erythema and flushing. The topical 0.33% formulation is applied directly to affected areas to provide localized anti-erythema effects.
Approved indications
- Persistent facial erythema associated with rosacea
Common side effects
- Erythema (rebound redness)
- Pruritus
- Skin irritation
- Pallor
Key clinical trials
- Brimonidine 0.33% for Rosacea-Related Facial Erythema (PHASE4)
- Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea (NA)
- Mirvaso in Use Study (PHASE4)
- Brimonidine in Rosacea (NA)
- Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea (PHASE3)
- MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (PHASE4)
- Treatment of Asian Flushing Syndrome With Topical Alpha Agonists (EARLY_PHASE1)
- Preferences & Treatment Satisfaction Drivers in Rosacea Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine 0.33% CI brief — competitive landscape report
- Brimonidine 0.33% updates RSS · CI watch RSS
- Derm Research, PLLC portfolio CI
Frequently asked questions about Brimonidine 0.33%
What is Brimonidine 0.33%?
How does Brimonidine 0.33% work?
What is Brimonidine 0.33% used for?
Who makes Brimonidine 0.33%?
Is Brimonidine 0.33% also known as anything else?
What drug class is Brimonidine 0.33% in?
What development phase is Brimonidine 0.33% in?
What are the side effects of Brimonidine 0.33%?
What does Brimonidine 0.33% target?
Related
- Drug class: All Alpha-2 adrenergic agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: Derm Research, PLLC — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Persistent facial erythema associated with rosacea
- Also known as: Miravaso, Onreltea
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing